Article thumbnail

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience

By Grzegorz Wladyslaw Basak, Wanda Knopinska-Posluszny, Magdalena Matuszak, Elzbieta Kisiel, Dorota Hawrylecka, Anna Szmigielska-Kaplon, Donata Urbaniak-Kujda, Jaroslaw Dybko, Patrycja Zielinska, Anna Dabrowska-Iwanicka, Joanna Werkun, Piotr Rzepecki, Wiktoria Wroblewska and Wieslaw Wiktor-Jedrzejczak


Recent developments in the field of targeted therapy have led to the discovery of a new drug, plerixafor, that is a specific inhibitor of the CXCR4 receptor. Plerixafor acts in concert with granulocyte colony-stimulating factor (G-CSF) to increase the number of stem cells circulating in the peripheral blood (PB). Therefore, it has been applied in the field of hematopoietic stem cell mobilization. We analyzed retrospectively data regarding stem cell mobilization with plerixafor in a cohort of 61 patients suffering from multiple myeloma (N = 23), non-Hodgkin’s lymphoma (N = 20), or Hodgkin’s lymphoma (N = 18). At least one previous mobilization attempt had failed in 83.6% of these patients, whereas 16.4% were predicted to be poor mobilizers. The median number of CD34+ cells in the PB after the first administration of plerixafor was 22/μL (range of 0–121). In total, 85.2% of the patients proceeded to cell collection, and a median of two (range of 0–4) aphereses were performed. A minimum of 2.0 × 106 CD34+ cells per kilogram of the patient’s body weight (cells/kg b.w.) was collected from 65.6% of patients, and the median number of cells collected was 2.67 × 106 CD34+ cells/kg b.w. (0–8.0). Of the patients, 55.7% had already undergone autologous stem cell transplantation, and the median time to neutrophil and platelet reconstitution was 12 and 14 days, respectively. Cases of late graft failure were not observed. We identified the diagnosis of non-Hodgkin’s lymphoma and previous radiotherapy as independent factors that contributed to failure of mobilization. The current report demonstrates the satisfactory efficacy of plerixafor plus G-CSF for stem cell mobilization in heavily pre-treated poor or predicted poor mobilizers

Topics: Original Article
Publisher: Springer-Verlag
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). A novel role of complement in mobilization: immunodeficient mice are poor granulocyte-colony stimulating factor mobilizers because they lack complementactivating immunoglobulins.
  2. (2008). Amd3100 plus g-csf can successfully mobilize cd34+ cells from non-hodgkin’s lymphoma, hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.
  3. (2000). Autologous peripheral blood progenitor cell Ann Hematol (2011) 90:557–568 567transplantation with <2×10(6) cd34(+)/kg: an analysis of variables concerning mobilisation and engraftment.
  4. (2009). Controversies in the treatment of lymphoma with autologous transplantation.
  5. (2004). Cxcr4-sdf-1 signalling, locomotion, chemotaxis and adhesion.
  6. (1992). Defining a therapeutic dose of peripheral blood stem cells.
  7. (2010). Effective stem cell mobilization with plerixafor + g-csf followed by large-volume leukapheresis in poor mobilizers: the experience of the croatian cooperative group for hematologic diseases(krohem).BoneMarrowTransplant45(Supplement2):S321
  8. (2003). Effects of high whole blood flow rates and high peripheral blood cell counts on cd34+ cell yield and cross-cellular contamination. Cytotherapy 5:446 568 Ann Hematol
  9. (1998). Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies.
  10. (1995). Factors that influence collection and engraftment of autologous peripheral-blood stem cells.
  11. (2009). Hematopoietic stem cell transplantation in multiple myeloma.
  12. (2008). Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
  13. (2009). Improving stem cell mobilization strategies: future directions.
  14. (2006). International uniform response criteria for multiple myeloma.
  15. (2007). Mobilization and collection of autologous hematopoietic progenitor/stem cells.
  16. (2010). Mobilization of peripheral blood stem cells for autologous transplant in nonhodgkin’s lymphoma and multiple myeloma patients by plerixafor and g-csf and detection of tumor cell mobilization by pcr in multiple myeloma patients.
  17. (2009). Plerixafor and g-csf versus placebo and g-csf to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
  18. (2010). Plerixafor for stem cell mobilization in poor mobilizers: results from the german compassionate use programme.
  19. (2010). Plerixafor plus g-csf can mobilize autologous haematopoietic stem cells from heavily pre-treated patients failing previous mobilization attempts: analysis of the french compassionate use programme.
  20. (2010). Plerixafor plus g-csf can successfully mobilize cd34+ cells from patients who have previously failed chemotherapy and/or cytokine mobilization: the compassionate use experience in austria.
  21. (2009). Rescue from failed growth factor and/or chemotherapy hsc mobilization with g-csf and plerixafor (amd3100): an institutional experience.
  22. (2007). Revised response criteria for malignant lymphoma.
  23. (2010). Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.
  24. (2010). Stem cell mobilization with plerixafor in poorly mobilizing myeloma and lymphoma patients—a single centre experience and strategies.
  25. (2010). The use of plerixafor in czech transplant centers. Bone Marrow Transplant 45(Supplement 2):S320
  26. (2009). Treatment with plerixafor in non-hodgkin’s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of g-csf: implications for the heavily pretreated patient.
  27. (2005). Urbano-Ispizua A